Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP- mediated tumor growth and metastasis

eLife

Volumn 5, Issue OCTOBER2016, 2016, Pages

  Nokin, Marie Julie ^a   Durieux, Florence ^a   Peixoto, Paul ^a   Chiavarina, Barbara ^a   Peulen, Olivier ^a   Blomme, Arnaud ^a   Turtoi, Andrei ^a   Costanza, Brunella ^a   Smargiasso, Nicolas ^a   Baiwir, Dominique ^a   Scheijen, Jean L ^b   Schalkwijk, Casper G ^b,c   Leenders, Justine ^a   De Tullio, Pascal ^a   Bianchi, Elettra ^d   Thiry, Marc ^a   Uchida, Koji ^e   Spiegel, David A ^f   Cochrane, James R ^g   Hutton, Craig A ^g   De Pauw, Edwin ^a   Delvenne, Philippe ^d   Belpomme, Dominique ^h   Castronovo, Vincent ^a   Bellahcène, Akeila ^a   more..

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e NAGOYA UNIVERSITY   (Japan)

^f YALE UNIVERSITY   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Cancer Research Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; METHYLGLYOXAL; TRANSCRIPTION FACTOR YAP1; ADVANCED GLYCATION END PRODUCT; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL GROWTH ASSAY; CHROMATIN IMMUNOPRECIPITATION; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITOMETRY; GENE EXPRESSION ASSAY; GENETIC TRANSFECTION; GLYCATION; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; STRESS; TUMOR GROWTH; VALIDATION PROCESS; WESTERN BLOTTING; AEROBIC METABOLISM; BREAST TUMOR; CELL PROLIFERATION; GLYCOSYLATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AEROBIOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOLYSIS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASM METASTASIS; PHOSPHOPROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRUVALDEHYDE;

EID: 84992709181     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.19375     Document Type: Article

References (71)

1. Ahmed N, Thornalley PJ. 2005. Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Annals of the New York Academy of Sciences 1043:260-266. doi: 10.1196/annals.1333.031
2. Antognelli C, Mezzasoma L, Fettucciari K, Mearini E, Talesa VN. 2013. Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells. The Prostate 73:121-132. doi: 10.1002/ pros.22547
3. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. 1999. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48:198-202. doi: 10.2337/diabetes.48.1.198
4. Bento CF, Marques F, Fernandes R, Pereira P. 2010. Methylglyoxal alters the function and stability of critical components of the protein quality control. PLoS One 5:e13007. doi: 10.1371/journal.pone.0013007
5. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnölzer M, Lasitschka F, Lasischka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, et al. 2012. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine 18:926-933. doi: 10.1038/nm.2750
6. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. 2006. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Sciences 31:164-172. doi: 10.1016/j.tibs.2006.01.006
7. Cheng WL, Tsai MM, Tsai CY, Huang YH, Chen CY, Chi HC, Tseng YH, Chao IW, Lin WC, Wu SM, Liang Y, Liao CJ, Lin YH, Chung IH, Chen WJ, Lin PY, Wang CS, Lin KH. 2012. Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS One 7: e34352. doi: 10.1371/journal.pone.0034352
8. Chiavarina B, Nokin MJ, Durieux F, Bianchi E, Turtoi A, Peulen O, Peixoto P, Irigaray P, Uchida K, Belpomme D, Delvenne P, Castronovo V, Bellahcène A. 2014. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 5:5472-5482. doi: 10. 18632/oncotarget.2121
9. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S. 2011. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147:759-772. doi: 10.1016/j.cell.2011.09.048
10. DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, Hsieh M, Zhu S, Asara JM, Zheng B, Bardeesy N, Liu J, Wu X. 2014. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Reports 9:495-503. doi: 10.1016/j.celrep.2014.09.036
11. Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ. 2006. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 55:1961-1969. doi: 10.2337/db05-1634
12. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S. 2011. Role of YAP/TAZ in mechanotransduction. Nature 474:179-183. doi: 10.1038/nature10137
13. Emi N, Friedmann T, Yee JK. 1991. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. Journal of Virology 65:1202-1207.
14. Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, Bicciato S, Dupont S. 2015. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. The EMBO Journal 34: 1349-1370. doi: 10.15252/embj.201490379
15. Fonseca-Sánchez MA, Rodríguez Cuevas S, Mendoza-Hernández G, Bautista-Piña V, Arechaga Ocampo E, Hidalgo Miranda A, Quintanar Jurado V, Marchat LA, Alvarez-Sánchez E, Pérez Plasencia C, López-Camarillo C. 2012. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. International Journal of Oncology 41:670-680. doi: 10.3892/ijo.2012.1478
16. Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, Hida T, Tsujimura T, Osada H, Sekido Y. 2012. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. The Journal of Experimental Medicine 209:479-494. doi: 10.1084/jem. 20111653
17. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. 2010. Diabetes and cancer: a consensus report. Diabetes Care 33:1674-1685. doi: 10.2337/dc10-0666
18. Han Y, Randell E, Vasdev S, Gill V, Curran M, Newhook LA, Grant M, Hagerty D, Schneider C. 2009. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. Clinical Biochemistry 42:562-569. doi: 10.1016/j.clinbiochem.2008.12.016
19. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. 2008. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. Journal of Biological Chemistry 283:5496-5509. doi: 10.1074/jbc.M709037200
20. Harvey KF, Zhang X, Thomas DM. 2013. The Hippo pathway and human cancer. Nature Reviews Cancer 13:246-257. doi: 10.1038/nrc3458
21. He M, Zhou Z, Shah AA, Hong Y, Chen Q, Wan Y. 2016. New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics. Cell Division 11: 4. doi: 10.1186/s13008-016-0013-6
22. Hiemer SE, Szymaniak AD, Varelas X. 2014. The transcriptional regulators TAZ and YAP direct transforming growth factor b-induced tumorigenic phenotypes in breast cancer cells. Journal of Biological Chemistry 289: 13461-13474. doi: 10.1074/jbc.M113.529115
23. Hipkiss AR, Chana H. 1998. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochemical and Biophysical Research Communications 248:28-32. doi: 10.1006/bbrc.1998.8806
24. Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, Katai H, Taniguchi H, Yanagihara K, Imoto I, Inazawa J, Ohki M, Shibata T. 2015. Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene 34:1196-1206. doi: 10.1038/onc.2014.57
25. Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM. 2010. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Research 70:8642-8650. doi: 10.1158/0008-5472.CAN-10-1345
26. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O’Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L, Ya-Hui Shiang C. 2011. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. Journal of the National Cancer Institute 103:264-272. doi: 10.1093/jnci/djq524
27. Kang Y, Edwards LG, Thornalley PJ. 1996. Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leukemia Research 20:397-405. doi: 10. 1016/0145-2126(95)00162-X
28. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. 2008. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and Cellular Biology 28: 2426. doi: 2436
29. Lund T, Svindland A, Pepaj M, Jensen AB, Berg JP, Kilhovd B, Hanssen KF. 2011. Fibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans. Diabetes and Vascular Disease Research 8:284-294. doi: 10.1177/1479164111416831
30. Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS, Guan KL. 2015. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nature Cell Biology 17:500-510. doi: 10.1038/ ncb3111
31. Moroishi T, Hansen CG, Guan KL. 2015. The emerging roles of YAP and TAZ in cancer. Nature Reviews Cancer 15: 73. doi: 79
32. Mulvihill MM, Benjamin DI, Ji X, Le Scolan E, Louie SM, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, Nomura DK. 2014. Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. Chemistry & Biology 21:831-840. doi: 10.1016/j.chembiol.2014.05.008
33. Nakayama K, Nakayama M, Iwabuchi M, Terawaki H, Sato T, Kohno M, Ito S. 2008. Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. American Journal of Nephrology 28:871-878. doi: 10.1159/000139653
34. Neckers L, Workman P. 2012. Hsp90 molecular chaperone inhibitors: are we there yet? Clinical Cancer Research 18:64-76. doi: 10.1158/1078-0432.CCR-11-1000
35. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng C-X, Brugge JS, Haber DA. 2006. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. PNAS 103: 12405-12410. doi: 10.1073/pnas.0605579103
36. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, Uchida K. 1999. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. The Journal of Biological Chemistry 274:18492-18502. doi: 10.1074/jbc.274.26.18492
37. Oya-Ito T, Naito Y, Takagi T, Handa O, Matsui H, Yamada M, Shima K, Yoshikawa T. 2011. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:769-781. doi: 10.1016/j.bbadis.2011.03.017
38. Pan D. 2010. The hippo signaling pathway in development and cancer. Developmental Cell 19:491-505. doi: 10. 1016/j.devcel.2010.09.011
39. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP, McQuade MM, Garner C, Digman MA, Teitell MA, Edwards RA, Gratton E, Waterman ML. 2014. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. The EMBO Journal 33:1454-1473. doi: 10.15252/embj.201488598
40. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW. 2005. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Research 65:4929-4938. doi: 10.1158/0008-5472.CAN-04-4458
41. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. 2013. Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology & Metabolism 24:469-480. doi: 10.1016/j.tem.2013.05.004
42. Rabbani N, Thornalley PJ. 2014. Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nature Protocols 9:1969-1979. doi: 10.1038/nprot. 2014.129
43. Radu BM, Dumitrescu DI, Mustaciosu CC, Radu M. 2012. Dual effect of methylglyoxal on the intracellular Ca2+ signaling and neurite outgrowth in mouse sensory neurons. Cellular and Molecular Neurobiology 32:1047-1057. doi: 10.1007/s10571-012-9823-5
44. Richard JP. 1993. Mechanism for the formation of methylglyoxal from triosephosphates. Biochemical Society Transactions 21:549-553. doi: 10.1042/bst0210549
45. Rowlands M, McAndrew C, Prodromou C, Pearl L, Kalusa A, Jones K, Workman P, Aherne W. 2010. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the TranscreenerTM ADP assay kit. Journal of Biomolecular Screening 15:279-286. doi: 10.1177/1087057109360253
46. Ryu TY, Park J, Scherer PE. 2014. Hyperglycemia as a risk factor for cancer progression. Diabetes & Metabolism Journal 38:330-336. doi: 10.4093/dmj.2014.38.5.330
47. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. 2001. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clinical Cancer Research 7:2513-2518.
48. Sakamoto H, Mashima T, Yamamoto K, Tsuruo T. 2002. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. Journal of Biological Chemistry 277:45770-45775. doi: 10. 1074/jbc.M207485200
49. Santarius T, Bignell GR, Greenman CD, Widaa S, Chen L, Mahoney CL, Butler A, Edkins S, Waris S, Thornalley PJ, Futreal PA, Stratton MR. 2010. GLO1-A novel amplified gene in human cancer. Genes, Chromosomes and Cancer 49:711-725. doi: 10.1002/gcc.20784
50. Scheijen JL, Schalkwijk CG. 2014. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. Clinical Chemistry and Laboratory Medicine 52:85-91. doi: 10.1515/cclm-2012-0878
51. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9:671-675. doi: 10.1038/nmeth.2089
52. Shen Y, Yang J, Li J, Shi X, Ouyang L, Tian Y, Lu J. 2014. Carnosine inhibits the proliferation of human gastric cancer SGC-7901 cells through both of the mitochondrial respiration and Glycolysis pathways. PLoS One 9: e104632. doi: 10.1371/journal.pone.0104632
53. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S. 2005. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clinical Cancer Research 11:1380-1385. doi: 10.1158/1078-0432.CCR-04-1773
54. Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ, Double J. 1996. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochemical Pharmacology 51:1365-1372. doi: 10.1016/0006-2952(96)00059-7
55. Thornalley PJ. 1996. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. General Pharmacology 27: 565-573. doi: 10.1016/0306-3623(95)02054-3
56. Thornalley PJ. 2005. Dicarbonyl intermediates in the maillard reaction. Annals of the New York Academy of Sciences 1043:111-117. doi: 10.1196/annals.1333.014
57. Tikellis C, Pickering RJ, Tsorotes D, Huet O, Cooper ME, Jandeleit-Dahm K, Thomas MC. 2014. Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 63:3915-3925. doi: 10.2337/db13-0932
58. Trepel J, Mollapour M, Giaccone G, Neckers L. 2010. Targeting the dynamic HSP90 complex in cancer. Nature Reviews Cancer 10:537-549. doi: 10.1038/nrc2887
59. Turk Z. 2010. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiological Research 59:147-156.
60. van Heijst JW, Niessen HW, Hoekman K, Schalkwijk CG. 2005. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Annals of the New York Academy of Sciences 1043:725-733. doi: 10.1196/annals.1333.084
61. van Heijst JW, Niessen HW, Musters RJ, van Hinsbergh VW, Hoekman K, Schalkwijk CG. 2006. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Letters 241:309-319. doi: 10.1016/j.canlet.2005.10.042
62. Waltregny D, Bellahcène A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewé W, de Leval J, Castronovo V. 1998. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. JNCI Journal of the National Cancer Institute 90:1000-1008. doi: 10.1093/jnci/90.13.1000
63. Wang T, Douglass EF, Fitzgerald KJ, Spiegel DA. 2013. A "turn-on" fluorescent sensor for methylglyoxal. Journal of the American Chemical Society 135:12429-12433. doi: 10.1021/ja406077j
64. Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, Chen J. 2015. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nature Cell Biology 17:490-499. doi: 10.1038/ncb3113
65. Ward PS, Thompson CB. 2012. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21:297-308. doi: 10.1016/j.ccr.2012.02.014
66. Xu CX, Zhu HH, Zhu YM. 2014. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World Journal of Diabetes 5:372-380. doi: 10.4239/wjd.v5.i3.372
67. Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, Neckers L. 2008. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. PNAS 105:15541-15546. doi: 10. 1073/pnas.0805354105
68. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. 2008. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135:852-864. doi: 10.1016/j.cell.2008.09.061
69. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL. 2009. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. Journal of Biological Chemistry 284:13355-13362. doi: 10.1074/jbc.M900843200
70. Zhang S, Liang X, Zheng X, Huang H, Chen X, Wu K, Wang B, Ma S. 2014. Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology 7:2079-2090.
71. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. 2008. TEAD mediates YAP-dependent gene induction and growth control. Genes & Development 22:1962-1971. doi: 10. 1101/gad.1664408